Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $6.33

Shares of Context Therapeutics Inc. (NASDAQ:CNTX) have received a consensus rating of “Buy” from the seven analysts that are currently covering the firm, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $6.33.

Several analysts recently weighed in on CNTX shares. Citizens Jmp raised Context Therapeutics to a “strong-buy” rating in a report on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Wednesday, January 15th. Finally, JMP Securities started coverage on Context Therapeutics in a research note on Wednesday, January 8th. They set an “outperform” rating and a $4.00 price objective on the stock.

Institutional Investors Weigh In On Context Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Clear Harbor Asset Management LLC boosted its holdings in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company’s stock valued at $61,000 after acquiring an additional 21,804 shares during the period. Franklin Resources Inc. bought a new stake in Context Therapeutics in the 3rd quarter valued at about $3,689,000. Y Intercept Hong Kong Ltd acquired a new position in Context Therapeutics during the 3rd quarter valued at about $89,000. State Street Corp boosted its stake in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after purchasing an additional 19,800 shares during the period. Finally, Renaissance Technologies LLC grew its position in Context Therapeutics by 63.4% in the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock worth $131,000 after purchasing an additional 25,300 shares during the last quarter. 14.03% of the stock is owned by institutional investors and hedge funds.

Context Therapeutics Price Performance

CNTX opened at $0.88 on Friday. Context Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.75. The stock has a market capitalization of $65.92 million, a PE ratio of -0.97 and a beta of 2.06. The firm’s fifty day moving average price is $1.17 and its 200 day moving average price is $1.80.

Context Therapeutics (NASDAQ:CNTX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). On average, equities research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.